MedTrace Logo

Sodium Excretion of LCZ696 in Patients With Hypertension; Heart Failure and Healthy Volunteers

NCT01353508 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2015-11-23

Study results available
· View outcomes & findings →

Summary

Assess mechanism of action of LCZ696 related to sodium excretion.

Conditions

Interventions

DRUG

LCZ696

200 mg and 400 mg tablets

DRUG

Valsartan

160 mg tablets

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2012-08-31
Completion
2012-08-31

Countries

  • Russia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01353508 on ClinicalTrials.gov